Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Chronic myeloid leukemia
Asciminib and the STAMP inhibitors, treatment-free remission and resistance after ponatinib.
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans · Blood 148 (Supplement 1)
The meeting is in December. Regular abstracts have been public since 4 Nov 2026 but the Blood supplement was not in Crossref on 11 Nov, so ASH abstracts here come from web research. Late-breaking abstracts are embargoed until 7 Dec and are not shown.
Headline and verified abstracts
29 abstracts found by Parallel web research on 2026-11-11 and verified: 29 checked on the source page. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- 91Oral presentation
- 92Oral presentation
- 93Oral presentationAdditional somatic mutations detected by serial single-molecule molecular inversion probe sequencing in a prospective cohort of newly diagnosed chronic myeloid leukemia: Insights on mutational dynamics from the prospective TCGA-GTA registryMaria Perusini, MD, MscVerified on source pageonlineprogram.hematology.org
- 94Oral presentationImmune surveillance after a second TKI stop in CML: Dasatinib-associated CD4+ T-cell modulation and tfr duration — first findings from the DASTOP2 studyPakize Ak, MSDASTOP2dasatinibVerified on source pageonlineprogram.hematology.org
- 95Oral presentationFrontline therapy with tyrosine kinase inhibitors (TKIs) may modify the frequency of mutated ASXL1 and the cell lineage in blast Phase (BP) CML: Insights from the international CML foundation (iCMLf) genomics alliance on the Harmony PlatformSusan Branford, PhDVerified on source pageonlineprogram.hematology.org
- 96Oral presentationLongitudinal myeloid-panel sequencing reveals a diverse spectrum of somatic mutation dynamics in asciminib-treated chronic myeloid leukemiaAna Flavia Patiño IV, MDasciminibVerified on source pageonlineprogram.hematology.org
- 1980Poster
- 1981PosterA dasatinib-enhanced adaptive natural killer cell therapy against TKI-resistant blast crisis chronic myeloid leukemiaVaidehi Krishnan, PhDdasatinibVerified on source pageonlineprogram.hematology.org
- 1982Poster
- 1984PosterPhase II trial of dasatinib in combination with ASTX727 in patients with newly diagnosed chronic myeloid leukemiaGeorgio Medawar, MDdasatinibASTX727Verified on source pageonlineprogram.hematology.org
- 1985Poster
- 1986PosterAsciminib once or twice daily demonstrates sustained efficacy, stable patient-reported outcomes, and favorable safety in patients with chronic myeloid leukemia resistant or intolerant to 2 or more tyrosine kinase inhibitors: Final results of the ASC4OPT studyAndreas Hochhaus, MDASC4OPTasciminibVerified on source pageonlineprogram.hematology.org
- 1987PosterWeek 96 interim analysis (IA) of efficacy and safety results in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) after 1 prior tyrosine kinase inhibitor (TKI)Ehab Atallah, MDASC2ESCALATEasciminibVerified on source pageonlineprogram.hematology.org
- 1988PosterEfficacy and safety of vamotinib versus high-dose imatinib in patients with chronic-phase CML resistant to standard-dose imatinib: 24-month Results of a multicenter randomized phase III studyAnna Turkina, MDvamotinibimatinibVerified on source pageonlineprogram.hematology.org
- 1989PosterOne-step single-molecule countable PCR enables cis/trans phasing of BCR-ABL1 compound mutations in TKI-resistant CMLYulei Shang, Ph.DVerified on source pageonlineprogram.hematology.org
- 1990Poster
- 1992Poster
- 1993Poster
- 1994PosterImpaired DNAM-1/NKp80 NK-cell activation and T-cell exhaustion at diagnosis precede suboptimal early molecular response in CMLLarissa Sarri Binelli SrVerified on source pageonlineprogram.hematology.org
- 1995PosterShort-course pomalidomide for maintaining treatment-free remission in CML-chronic Phase after TKI discontinuation: Early results of an ongoing Phase II trialHasmukh Jain, MDpomalidomideVerified on source pageonlineprogram.hematology.org
- 1996PosterAssociation of somatic mutations with long-term outcomes of ponatinib treatment in chronic Phase chronic myeloid leukemia.Olga Kulemina, MDponatinibVerified on source pageonlineprogram.hematology.org
- 1997Poster
- 1998Poster
- 3743PosterValidation of a prognostic score in blast phase CML: A cure CML consortium analysisAkriti G Jain, MD, FACPVerified on source pageonlineprogram.hematology.org
- 3744PosterDeep molecular response and treatment-free remission with dasatinib plus venetoclax in newly diagnosed chronic myeloid leukemiaDany Nassar, MDdasatinibvenetoclaxVerified on source pageonlineprogram.hematology.org
- 3745PosterLong-term outcomes with vodobatinib in heavily pre-treated chronic Phase CML: Phase 1/2 study analysisJorge Cortes, MDvodobatinibVerified on source pageonlineprogram.hematology.org
- 3759Poster
- 5511PosterCD19-directed CAR T-cell therapy with brexucabtagene autoleucel or obecabtagene autoleucel produces durable remission for CML patients in lymphoid blast phase: A rocca consortium multicenter analysisSinan Cetin, MDbrexucabtagene autoleucelobecabtagene autoleucelponatinibasciminibVerified on source pageonlineprogram.hematology.org
- 6333PosterRacial disparities in survival outcomes in CML in the era of expanding TKI availability: A two-decade, SEER population-based analysis (2001–2023)Muhammad Alamgir Khan, MDVerified on source pageonlineprogram.hematology.org
Indexed in Crossref
The ASH Annual Meeting 2026 supplement (Blood 148 (Supplement 1)) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.